News from the FDA/CDC

First IL-23 blocker, guselkumab, earns FDA approval for psoriasis


 

Guselkumab, a monoclonal antibody that targets interleukin (IL)-23, has been approved by the Food and Drug Administration for treating moderate to severe plaque psoriasis, based on three phase 3 studies of more than 2,000 adults, the manufacturer announced July 13.

The approved indication is for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, according to a press release issued by Janssen Biotech, which stated that this is the first IL-23 blocker approved for psoriasis.

Guselkumab is administered subcutaneously, at a dose of 100 mg every 8 weeks, after two initial doses at weeks 0 and 4.

Results of one of the phase 3 trials, VOYAGE 1, included a significantly greater proportion of patients treated with guselkumab achieving at least a 90% improvement in the Psoriasis Area Severity Index (PASI 90) at 16 weeks, compared with placebo (73.3% vs. 2.9%). At 16 weeks, 85.1% of those treated with guselkumab achieved an Investigator’s Global Assessment (IGA) score of 0 (cleared) or 1 (minimal disease), compared with 6.9% of those on placebo. Superior responses continued through 48 weeks.

In an active comparator arm of the study comparing guselkumab with the TNF blocker adalimumab (Humira), a significantly higher proportion of those treated with guselkumab achieved PASI 90 scores (76.3% vs. 47.9%) and IGA 0/1 scores (80.5% vs. 55.4%) at week 48. The results were published in March (J Am Acad Dermatol. 2017 Mar;76[3]:405-17).

Results of VOYAGE 2 comparing guselkumab with adalimumab included a PASI 90 rate of 66.1% at week 48 among adalimumab nonresponders who switched to guselkumab (J Am Acad Dermatol. 2017 Mar;76[3]:418-31).

The most common serious adverse effects associated with treatment included upper respiratory infections, headache, injection site reactions, arthralgias, diarrhea, gastroenteritis, fungal skin infections, and herpes simplex infections, according to the company statement.

Phase 3 studies of guselkumab for active psoriatic arthritis and in comparison with secukinumab (Cosentyx) in patients with moderate to severe plaque psoriasis are underway, according to Janssen, which is marketing guselkumab as Tremfya.

Recommended Reading

Renflexis approved as second infliximab biosimilar
MDedge Rheumatology
Study underscores antipsoriatic effect of gastric bypass surgery
MDedge Rheumatology
Some data support botulinum toxin for psoriasis and rosacea
MDedge Rheumatology
Adalimumab outperforms methotrexate in treating severe pediatric plaque psoriasis
MDedge Rheumatology
Experts endorse routine screening for pediatric psoriasis comorbidities
MDedge Rheumatology
Pain often persists despite biologic treatment in PsA
MDedge Rheumatology
TWEAKing inflammation: Studies reflect potential treatment target for psoriasis, atopic dermatitis
MDedge Rheumatology
Early phase III data positive for adalimumab biosimilar, for both psoriasis and PsA
MDedge Rheumatology
FDA approves abatacept for adults with psoriatic arthritis
MDedge Rheumatology
Comorbidities in psoriatic arthritis flag worse prognosis
MDedge Rheumatology

Related Articles